European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Name of Questionnaire
European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30 v.
Cancer-specific core questionnaire for use in relation to
various cancers. May be used in conjunction with the lung
EORTC Quality of Life Study Group
Quality of Life Unit
EORTC Data CenterAvenue
E. Mounier 83, Bte 11B-1200
Tel: +32 2 774 16 06
Fax: +32 2 779 45 68
Cost & availability
Free for university research, fee for use in pharmaceutical
Time to complete
Under 10 minutes
Number of items
Domains & categories
Name of categories/domains
Functional scales (physical, role, cognitive, emotional,
social), symptom scales (fatigue, pain, and nausea and vomiting),
global health status and quality of life scale, also several
single-item symptom measures
Scaling of items
1 (Not at all) to 4 (Very much), 1 (Very poor) to 7
0 to 100. For functional and global quality of life scales,
higher scores mean a better level of functioning. For
symptom-oriented scales, a higher score means more severe
|a. Test-retest/ reproducibility
|b. Internal consistency
Scales were found to assess distinct components of quality of
life2. Instrument was found to
distinguish between patients with different performance status and
degrees of weight loss2. Statistically
significant changes, in the expected direction, in physical and
role functioning, global quality of life, fatigue, and nausea and
vomiting, for patients whose performance status had improved or
worsened during treatment2. Detected
effect of palliative radiotherapy over time4.
Minimally important difference
5 to 10 points5
Reported : after resection of non-small cell lung cancer6,8, quality of life in cancer
patients receiving chemotherapy9.
With QLQ-LC13: Reported : MVP chemotherapy in small cell lung
cancer12, chemotherapy in advanced
small cell lung cancer17.
Not reported in patients with lung cancer
Afrikaans, Arabic, Bulgarian, Chinese, Croatian, Czech, Danish,
Dutch, English (American, Australian, British, Canadian), Finnish,
French, German, Greek, Hebrew, Hungarian, Iranian, Italian,
Japanese, Lithuanian, Norwegian, Polish, Portuguese (Brazilian,
Portuguese), Romanian, Russian, Serbian, Slovakian, Slovenian,
Spanish (American, Argentinean, Spanish), Swedish, Turkish.
Pending: Chinese (Taiwanese), French (Canadian), Hindi, Korean,
- Hjermstad MJ, Fossa SD, Bjordal K, Kaasa
S. Test/retest study of the European Organization for Research and
Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin
Oncol 1995; 13:1249-54.
- Aaronson NK, Ahmedzai S, Bergman B, et
al. The European Organization for Research and Treatment of Cancer
QLQ-C30: a quality-of-life instrument for use in international
clinical trials in oncology. J Natl Cancer Inst. 1993;
- Osoba D, Aaronson N, Zee B, et al.
Modification of the EORTC QLQ-C30 (version 2.0) based on content
validity and reliability testing in large samples of patients with
cancer. The Study Group on Quality of Life of the EORTC and the
Symptom Control and Quality of Life Committees of the NCI of Canada
Clinical Trials Group. Qual Life Res 1997; 6:103-8.
- Kaasa S, Bjordal K, Aaronson N, et al.
The EORTC core quality of life questionnaire (QLQ-C30): validity
and reliability when analysed with patients treated with palliative
radiotherapy. Eur J Cancer 1995; 31A:2260-3.
- Osoba D, Rodrigues G, Myles J, Zee B,
Pater J. Interpreting the significance of changes in health-related
quality-of-life scores. J Clin Oncol 1998; 16:139-44.
- Zieren HU, Muller JM, Hamberger U, et
al. Quality of life after surgical therapy of bronchogenic
carcinoma. Eur J Cardiothorac Surg 1996; 10:233-7.
- Hendriks J, Van Schil P, Van Meerbeeck
J, et al. Short-term survival after major pulmonary resections for
bronchogenic carcinoma. Acta Chir Belg 1996; 96:273-79.
- Pater JL, Zee B, Palmer M, et al.
Fatigue in patients with cancer: results with National Cancer
Institute of Canada Clinical Trials Group studies employing the
EORTC QLQ-C30. Support Care Cancer 1997; 5:410-3.
- Dancey J, Zee B, Osoba D, et al. Quality
of life scores: an independent prognostic variable in a general
population of cancer patients receiving chemotherapy. The National
Cancer Institute of Canada Clinical Trials Group. Qual Life Res
- Hickish TF, Smith IE, Nicolson MC, et
al. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin)
chemotherapy in small-cell lung cancer. Br J Cancer 1998;
- Giaccone G, Splinter TA, Debruyne C,
et al. Randomized study of paclitaxel-cisplatin versus
cisplatin-teniposide in patients with advanced non-small cell lung
cancer. The European Organization for Research and Treatment of
Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998;
- Joss RA, Bacchi M, Hurny C, et al.
Early versus late alternating chemotherapy in small-cell lung
cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol
- Joss RA, Alberto P, Hurny C, et al.
Quality versus quantity of life in the treatment of patients with
advanced small-cell lung cancer? A randomized phase III comparison
of weekly carboplatin and teniposide versus cisplatin, adriamycin,
etoposide alternating with cyclophosphamide, methotrexate,
vincristine and lomustine. Swiss Group for Clinical Cancer Research
(SAKK). Ann Oncol 1995; 6:41-8.
- Bernhard J, Hurny C, Bacchi M, et al.
Initial prognostic factors in small-cell lung cancer patients
predicting quality of life during chemotherapy. Swiss Group for
Clinical Cancer Research (SAKK). Br J Cancer 1996; 74:1660-7.
- Kosmidis P, Mylonakis N, Fountzilas G,
et al. Paclitaxel (175mg/m2) plus carboplatin versus paclitaxel
(225 mg/m2) plus carboplatin in non-small cell lung cancer: a
randomized study. Semin Oncol 1997; 24:S12-30-S12-33.
- Herndon JE, 2nd, Fleishman S, Kosty
MP, et al. A longitudinal study of quality of life in advanced
non-small cell lung cancer: Cancer and Leukemia Group B (CALGB)
8931. Control Clin Trials 1997; 18:286-300.
Date of information